Search - tctmd.com

Displaying 1 - 20 of 101

Sort: Relevancy | Date

Presentation TCT 2016

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Ganesh Manoharan

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Think Twice: BRS First

Presenter: George D. Dangas, Fabio Felice Tarantino, Francesco Saia

November 01, 2016

Presentation TCT 2016

Choose a Drug-Eluting Stent: Heres Why

Presenter: George D. Dangas, Fabio Felice Tarantino, Carlo Cernetti

November 01, 2016

Presentation TCT 2016

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

Case 4:

Presenter: Parag Barwad, Raju Narasa Kavalipati, Narenda N. Khanna, Fazila T. Malik, Manotosh Panja, Gokul M. Reddy, Kamal K. Sethi, Jamshed J. Dalal

October 31, 2016

Presentation TCT 2016

Case 3:

Presenter: Parag Barwad, Raju Narasa Kavalipati, Narenda N. Khanna, Fazila T. Malik, Manotosh Panja, Gokul M. Reddy, Kamal K. Sethi, Rabin dra Nath Chakraborty

October 31, 2016

Presentation TCT 2016

Case 1:

Presenter: Parag Barwad, Raju Narasa Kavalipati, Narenda N. Khanna, Fazila T. Malik, Manotosh Panja, Gokul M. Reddy, Kamal K. Sethi, M.S. Hiremath

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TVT 2016

PARTNER Echocardiography Observations on Valve Durability

Presenter: Rebecca T. Hahn

June 17, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Highlights From PARTNER 2A in Intermediate-Risk Patients

Presenter: Michael J. Mack

June 16, 2016

Presentation TCT 2015

PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves

Presenter: John D. Carroll, Ioanna Kosmidou, Danny Dvir

October 15, 2015

Presentation TCT 2015

PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves

Presenter: Danny Dvir

October 15, 2015

Presentation TCT 2015

FDA-Approved or US IDE Studies: SAPIEN 3 - Technical Specifications and Clinical Trial Results (CE Studies and PARTNER II S3HR and S3i)

Presenter: Ariel Finkelstein, Ganesh Manoharan, Susheel Kodali

October 14, 2015

Presentation TCT 2015

Closing Remarks

Presenter: Rabin dra Nath Chakraborty, Angela Hoye

October 11, 2015

Advertisement

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Case Conclusion: How Did We Treat Our Patient?

Think Twice: BRS First

Choose a Drug-Eluting Stent: Heres Why

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Case 4:

Case 3:

Case 1:

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

PARTNER Echocardiography Observations on Valve Durability

Study Design for the PARTNER 3 Low-Risk Trial

Highlights From PARTNER 2A in Intermediate-Risk Patients

PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves

PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves

FDA-Approved or US IDE Studies: SAPIEN 3 - Technical Specifications and Clinical Trial Results (CE Studies and PARTNER II S3HR and S3i)

Closing Remarks

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content